EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis

Jung-Min Han, Kyu-Young Oh, Su-Jung Choi, Won-Woo Lee, Bo-Hwan Jin, Ji-Hoon Kim, Hyun-Ju Yu, Ryan Jin Young Kim, Hye-Jung Yoon, Jae-Il Lee, Seong-Doo Hong, Sung-Dae Cho

Cellular Oncology · 2025

DOI: 10.1007/s13402-024-00962-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, 2025. Verfasst von Jung-Min Han und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. Hauptthemen laut MEDLINE: Afatinib, Myeloid Cell Leukemia Sequence 1 Protein, Mouth Neoplasms, TOR Serine-Threonine Kinases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Seoul National University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

This study investigates the role and effectiveness of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) in oral cancer, focusing on the clinical relevance of EGFR and myeloid cell leukemia-1 (Mcl-1) in head and neck cancers (HNCs). It aims to explore the molecular mechanism of afatinib, a TKI, in treating human oral cancer.

Methods

We conducted an in silico analysis using databases like The Cancer Genome Atlas, Gene Expression Omnibus, and Clinical Proteomic Tumor Analysis Consortium, along with immunohistochemistry staining, to study EGFR and Mcl-1 expression in HNCs. For investigating afatinib’s anticancer properties, we performed various in vitro and in vivo analyses, including trypan blue exclusion assay, Western blotting, 4′-6-diamidino-2-phenylindole staining, flow cytometry, quantitative real-time PCR, Mitochondrial membrane potential assay, overexpression vector construction, transient transfection, and a tumor xenograft model.

Results

Higher expression levels of EGFR and Mcl-1 were observed in HNC patient tissues compared to normal tissues, with their co-expression significantly linked to poor prognosis. There was a strong correlation between EGFR and Mcl-1 expressions in oral cancer patients. Afatinib treatment induced apoptosis and suppressed Mcl-1 in oral cancer cell lines without the EGFR T790M mutation. The mechanism of afatinib-induced apoptosis involved the EGFR/mTOR/Mcl-1 axis, as shown by the effects of mTOR activator MHY1485 and inhibitor rapamycin. Afatinib also increased Bim expression, mitochondrial membrane permeabilization, and cytochrome c release. It significantly lowered tumor volume without affecting body, liver, and kidney weights.

Conclusion

Afatinib, targeting the EGFR/mTOR/Mcl-1 axis, shows promise as a therapeutic strategy for oral cancer, especially in patients with high EGFR and Mcl-1 expressions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AfatinibMyeloid Cell Leukemia Sequence 1 ProteinMouth NeoplasmsTOR Serine-Threonine KinasesSignal TransductionAntineoplastic AgentsQuinazolinesHumansErbB ReceptorsAnimalsCell Line, TumorXenograft Model Antitumor AssaysApoptosisMice, NudeFemaleMaleMiceMutationCell ProliferationGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

AfatinibEpidermal growth factor receptorHead and neck cancerMammalian target of rapamycinMyeloid cell leukemia-1

Substanzen

AfatinibMyeloid Cell Leukemia Sequence 1 ProteinErbB ReceptorsTOR Serine-Threonine KinasesAntineoplastic AgentsMCL1 protein, humanEGFR protein, humanMTOR protein, humanQuinazolines

Autor:innen und Institutionen

  • Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
  • Department of Oral Pathology, College of Dentistry, Dankook University, Cheonan, 31116, Republic of Korea.
  • Laboratory Animal Center, CHA University, CHA Biocomplex, Sampyeong-Dong, Seongnam, 13488, Republic of Korea.
  • Department of Dental Science, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea.
  • Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. hongsd@snu.ac.kr.
  • Department of Oral Pathology, School of Dentistry and Dental Research Institute, Seoul National University, Seoul, 03080, Republic of Korea. efiwdsc@snu.ac.kr.

Förderung

  • Seoul National University

Zitieren

APA

Han, J. M., Oh, K. Y., Choi, S. J., Lee, W. W., Jin, B. H., Kim, J. H., Yu, H. J., Kim, R. J. Y., Yoon, H. J., Lee, J. I., Hong, S. D., & Cho, S. D. (2025). Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis. Cellular Oncology. https://doi.org/10.1007/s13402-024-00962-6

Vancouver

Han JM, Oh KY, Choi SJ, Lee WW, Jin BH, Kim JH, et al. Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis. Cellular Oncology. 2025. doi:10.1007/s13402-024-00962-6

BibTeX
@article{Han2025,
  author = {Han, Jung-Min and Oh, Kyu-Young and Choi, Su-Jung and Lee, Won-Woo and Jin, Bo-Hwan and Kim, Ji-Hoon and Yu, Hyun-Ju and Kim, Ryan Jin Young and Yoon, Hye-Jung and Lee, Jae-Il and Hong, Seong-Doo and Cho, Sung-Dae},
  title = {Antitumor activity of afatinib in EGFR T790M-negative human oral cancer therapeutically targets mTOR/Mcl-1 signaling axis},
  journal = {Cellular Oncology},
  year = {2025},
  doi = {10.1007/s13402-024-00962-6}
}
Kostenlos starten →